nach oben

Reactions Weekly

Erschienen in:

01.06.2019 | Case report

Fingolimod/ocrelizumab

Severe rebound and worsening of relapsing-remitting multiple sclerosis: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Schmidt S, et al. Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases. Therapeutic Advances in Neurological Disorders 12: 6 May 2019. Available from: URL: http://doi.org/10.1177/1756286419846818 - Germany

Titel: Fingolimod/ocrelizumab
Severe rebound and worsening of relapsing-remitting multiple sclerosis: 2 case reports
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-63724-4

Springer Medizin

Fingolimod/ocrelizumab

Severe rebound and worsening of relapsing-remitting multiple sclerosis: 2 case reports

Excerpt

Weitere Artikel der Ausgabe 1/2019

Secukinumab

Tamoxifen

Hyaluronic acid

Quetiapine overdose

Apixaban/rivaroxaban

Antineoplastics/immunosuppressants

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Secukinumab

Tamoxifen

Hyaluronic acid

Quetiapine overdose

Apixaban/rivaroxaban

Antineoplastics/immunosuppressants